EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%
Titel:
EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%
Auteur:
Sriuranpong, V. Altundag, O. Clingan, P. Rizvi, N. Aren Frontera, O. Sezer, A. Paydas, S. Shavdia, M. Bondarenko, I. Gladkov, O. Lee, S. Li, S. Snodgrass, P. Rietschel, P.